Statement on Glucagen Hypokit supply 2 August 2023 Novo Nordisk has notified the Therapeutic Goods Administration that the Glucagen Hypokit is currently in a shortage that will last until 30 September 2023. The Glucagen Hypokit is used to treat severe hypoglycaemia where a person is unconscious or unable to take oral hypo treatments. If a person has a severe hypo and you don’t have a Hypokit you need to call 000 immediately. Diabetes Australia is working with the diabetes sector and the TGA to ensure people at highest risk are prioritized access to available supply. The TGA have also activated Section 19A provisions and is arranging imports of Hypokits from other countries. If you have concerns please talk to someone from your diabetes healthcare team.
News 11 March 2026 Support for people living with diabetes affected by floods Diabetes Australia extends its thoughts to the individuals, families, and communities affected by the flooding across Queensland and the Northern Territory. Continue Reading
News 16 January 2026 Wegovy to be listed on PBS The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended Wegovy (semaglutide) be subsidised through the Pharmaceutical Benefits Scheme (PBS) for adults with established cardiovascular disease and obesity. Diabetes Australia’s Group CEO... Continue Reading
News 18 December 2025 A merry, bright and healthy festive season for Australians living with diabetes As Australians prepare for a festive season filled with food, family and good wishes, people living with diabetes are being... Continue Reading
